Analysts expect Kadmon Holdings Inc (NYSE:KDMN) to announce sales of $2.75 million for the current quarter, according to Zacks. Two analysts have made estimates for Kadmon’s earnings, with the highest sales estimate coming in at $5.23 million and the lowest estimate coming in at $260,000.00. Kadmon posted sales of $230,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 1,095.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 5th.
According to Zacks, analysts expect that Kadmon will report full-year sales of $2.59 million for the current financial year, with estimates ranging from $900,000.00 to $5.92 million. For the next fiscal year, analysts anticipate that the company will post sales of $16.54 million, with estimates ranging from $860,000.00 to $38.56 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Kadmon.
Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald lifted their price target on Kadmon from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a report on Friday, January 24th. ValuEngine upgraded Kadmon from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, Nomura assumed coverage on Kadmon in a report on Friday, January 10th. They set a “buy” rating and a $10.00 price target for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $9.84.
NYSE:KDMN traded down $0.11 on Friday, hitting $4.52. 899,500 shares of the company’s stock traded hands, compared to its average volume of 1,616,890. The company has a current ratio of 2.29, a quick ratio of 2.29 and a debt-to-equity ratio of 0.54. Kadmon has a 1 year low of $1.63 and a 1 year high of $5.38. The firm has a 50-day moving average price of $4.57 and a 200-day moving average price of $3.51. The company has a market cap of $603.71 million, a PE ratio of -5.87 and a beta of 2.47.
In other Kadmon news, major shareholder Perceptive Advisors Llc purchased 1,470,588 shares of the company’s stock in a transaction on Monday, November 18th. The shares were bought at an average cost of $3.40 per share, with a total value of $4,999,999.20. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 2.85% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in KDMN. Marshall Wace LLP boosted its holdings in Kadmon by 343.1% in the first quarter. Marshall Wace LLP now owns 147,362 shares of the company’s stock worth $389,000 after purchasing an additional 114,108 shares during the period. Bank of New York Mellon Corp boosted its holdings in Kadmon by 9.3% in the second quarter. Bank of New York Mellon Corp now owns 407,211 shares of the company’s stock worth $839,000 after purchasing an additional 34,555 shares during the period. Parametric Portfolio Associates LLC acquired a new position in Kadmon in the second quarter worth $30,000. BlackRock Inc. boosted its holdings in Kadmon by 23.5% in the second quarter. BlackRock Inc. now owns 8,428,750 shares of the company’s stock worth $17,363,000 after purchasing an additional 1,605,568 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Kadmon by 5.9% in the second quarter. Vanguard Group Inc. now owns 5,713,561 shares of the company’s stock valued at $11,770,000 after buying an additional 320,710 shares during the last quarter. Institutional investors and hedge funds own 76.74% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: Why Invest in Dividend Achievers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.